Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19756273 | 0.90 | KDM4E (0.36) | KDM4EALDH1A1PKMMMP1KIFC1 | |
| SCHEMBL24328216 | 0.83 | TACR1 (0.36) | — | |
| SCHEMBL21536833 | 0.83 | GRIA1 (0.37) | MMP1 | |
| SCHEMBL21540322 | 0.81 | KDM4E (0.34) | KDM4EALDH1A1PKMMMP1DNM1 | |
| SCHEMBL19756279 | 0.81 | KDM4E (0.34) | KDM4EALDH1A1PKMMMP1KIFC1 | |
| SCHEMBL21285412 | 0.79 | KDM4E (0.33) | KDM4EALDH1A1PKMMMP1KIFC1 | |
| SCHEMBL16589732 | 0.79 | KDM4E (0.36) | KDM4EALDH1A1PKMMMP1DNM1 | |
| SCHEMBL16589713 | 0.78 | GRIA1 (0.37) | KDM4EALDH1A1PKMMMP1DNM1 | |
| SCHEMBL16589717 | 0.76 | KDM4E (0.37) | KDM4EALDH1A1PKMKIFC1AVPR1A | |
| SCHEMBL16589716 | 0.74 | KDM4E (0.36) | KDM4EALDH1A1PKMKIFC1AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220118053-A1 | Dry Pharmaceutical Formulations of CNP Conjugates | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220118053-A1 | Dry Pharmaceutical Formulations of CNP Conjugates | CNP, PTMS, NPPA | KDM4E 4574/4885ALDH1A1 1190/4885PKM 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.